 | | Vol. 15.04 – 2 February, 2024 |
| |
|
|
| Researchers hypothesized that tumor-accumulated prostate-specific membrane antigen (PSMA)-nanobubbles combined with low frequency unfocused therapeutic US would lead to selective damage and induce a specific therapeutic effect in PSMA-expressing tumors compared to PSMA-negative tumors.
[Bioactive Materials] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The inhibitory effects of bare black phosphorus nanomaterials and nanocomposites on the migration and invasion of bone cancer, breast cancer, and prostate cancer cells were assessed in vitro to determine the anticancer potential of nanomaterials against primary and secondary bone cancers.
[Bioactive Materials] |
|
|
|
| Scientists found ACP1 up-regulated in human prostate tumors and ACP1 expression inversely correlated with overall survival. Using CRISPR-Cas9–generated LMPTP knockout C4-2B and MyC-CaP cells, they identified LMPTP as a critical promoter of prostate cancer growth and bone metastasis.
[Science Advances] |
|
|
|
| Patients with metastatic castration-resistant prostate cancer refractory to androgen receptor pathway inhibitor therapy and taxane-based chemotherapy received target acapatamab doses ranging from 0.003 mg–0.9 mg in dose exploration and 0.3 mg in dose expansion intravenously Q2W.
[Clinical Cancer Research] |
|
|
|
| In male mouse osteoblasts and human prostate cancer cells, dihydrotestosterone induced the expression of Ctnnb1 and CTNN1B, respectively, as well as β-catenin target genes, stimulating the proliferation, survival, and differentiation of osteoblasts and the proliferation of prostate cancer cells in a PKG2-dependent fashion.
[Science Signaling] |
|
|
|
| Researchers discovered that EXO1 acted as a novel biomarker of prostate cancer, which promoted prostate cancer progression by regulating lipid metabolism reprogramming in prostate cancer cells.
[Journal Of Translational Medicine] |
|
|
|
| Scientists presented a practical and efficient approach to administer Gefitinib, encompassing the utilization of biocompatible nanostructures as a vehicle for drug delivery to augment its bioaccessibility and curative potency.
[Biomaterials Science] |
|
|
|
| CCT020312 is a selective PERK activator and may have a potential anti-tumor effect. Researchers investigated the anti-prostate cancer effect and its underlying mechanism of CCT020312.
[Biochemical Pharmacology] |
|
|
|
| The authors investigated the effectiveness and molecular characteristics of Docetaxel and radiation combination therapy in vitro.
[International Journal Of Radiation Biology] |
|  |
|
|
|
| Scientists focus on copper homeostasis and cuproptosis as well as recent findings on copper and cuproptosis in urological malignancies.
[Medical Research Reviews] |
|
|
|
|
| Researchers report that open-access papers have a greater reach than paywalled ones in two key ways: They attract more total citations, and those citations come from scholars in a wider range of locations, institutions, and fields of research.
[ScienceInsider] |
|
|
|
|
| March 21 – 23, 2024
Tokyo, Japan |
|
|
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Pfizer – Multiple Locations, United States |
|
|
|
| | Karolinska Institutet – Solna, Sweden |
|
|
|
| | The Vancouver Prostate Centre – Vancouver, British Columbia, Canada |
|
|
|
| | Jefferson-Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
